XML 30 R10.htm IDEA: XBRL DOCUMENT
v3.20.2

Business Combination | 9 Months Ended
--- | ---
Sep. 30, 2020
Business Combinations [Abstract] |
Business Combination | Business Combination On January 17, 2020, we completed the acquisition of all of the outstanding shares of InstruNor AS, a privately held Norwegian company (InstruNor). InstruNor is a provider of the only fully integrated sample preparation system for flow and mass cytometry. The acquisition of InstruNor supports our entry into the sample preparation market for cytometry analysis and expands our capabilities to include fully automated sample preparation for flow and mass cytometry. The value of this technology is reflected in the intangible asset for developed technology. The developed technology was valued using a discounted cash flow model for which the most sensitive assumption was revenue growth rate. The purchase price of $7.2 million included approximately $5.2 million in cash and 485,451 shares of our common stock valued at the closing price on the effective date of $4.22. A summary of the net cash flows is summarized below (in thousands):
|  | January 17, 2020
Cash consideration paid to former equity holders |  | $ | 5,165 |
Less: cash and cash equivalents acquired |  | (11) |
Acquisition of InstruNor, net of cash acquired |  | $ | 5,154 |
The acquisition was accounted for in accordance with ASC 805, Business Combinations. The assets acquired and liabilities assumed were recorded at their estimated fair values at the InstruNor acquisition date. Goodwill of $2.2 million was calculated as the purchase price less the fair value of the net assets acquired as follows (in thousands):
|  | January 17, 2020
Purchase price: |  |
Cash consideration paid on closing to former equity holders |  | $ | 5,165 |
Non-cash consideration common shares |  | 2,049 |
Total purchase price |  | $ | 7,214 |
Assets acquired: |  |
Cash and cash equivalents |  | $ | 11 |
Accounts receivable |  | 32 |
Other receivables |  | 13 |
Inventories, net |  | 153 |
Developed technology |  | 5,380 |
Liabilities assumed: |  |
Accounts payable |  | 14 |
Other current liabilities |  | 15 |
Deferred tax liability, net |  | 566 |
Fair value of identifiable net assets acquired |  | $ | 4,994 |
Goodwill acquired on acquisition |  | $ | 2,220 |

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration